Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
Date:11/6/2012

74622,7276,253  Total revenues

1,4853,45925,65110,643Operating ExpensesCost of manufacturing services

1.3961,5572,8396,215Research and development

11,61914,97840,16545,616General and administrative

7,3926,02918,96318,996Restructuring charges

0003,467Amortization of acquired technology & other intangibles

168197517819  Total operating expenses

20,57522,76162,48475,113Interest and Other Income (Expense)Interest income

412081102Interest expense

(1,804)(3,211)(7,324)(11,087)Gain (Loss) from valuation of derivative liabilities

5,259(233)(13,886)387Loss on extinguishment of debt

00(6,338)(10,514)Other

73(10)10340  Total interest and other income (expense), net

3,569(3,434)(27,364)(21,072)Net loss

(15,521)(22,736)(64,197)(85,542)Deemed dividend related to beneficial conversion

  feature of convertible preferred stock

00(2,824)(2,260)Net loss allocable to common stockholders

$(15,521)$(22,736)$(67,021)$(87,802)Net loss per share allocable to common stockholders:Basic

$
(0.07)$
(0.16)$
(0.35)$
(0.64)Diluted

$
(0.07)$
(0.16)$
(0.35)$
(0.64)Shares used in calculating net loss per share allocable

to common stockholders:Basic

213,881145,965189,545136,860Diluted

213,881145,965189,545136,860Arena Pharmaceuticals, Inc.Condensed Consolidated Balance Sheet Data(In thousands)September 30, 2012December 31, 2011(unaudited)1Assets  Cash and cash equivalents

$ 165,774$ 57,632  Accounts receivable

672607  Inventory

2,8080  Prepaid expenses & other current assets

4,4392,021  Land, property & equipment, net

76,03082,066  Acquired technology & other non-current assets

14,43714,803Total assets

$ 264,160$ 157,129Liabilities and Stockholders'
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
2. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
4. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
5. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
6. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
7. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
8. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
9. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
10. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... has priced its previously announced public offering of common ... will issue 23,529,412 common shares at a price of ... $2.0 billion. The Company will file a final prospectus ... S-3 and will make a similar filing with the ...
(Date:6/18/2013)...  Actavis, Inc. (NYSE: ACT ) today announced ... Securities and Exchange Commission (SEC) a registration statement on Form ... Chilcott plc (NASDAQ: WCRX ), which included ... (the "Form S-4"). As previously announced on ... entered into a definitive agreement pursuant to which Actavis will ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
(Date:6/19/2013)... Pharmaceutical history is replete with ... with little or no understanding why they work, ... involved emerging years later. When Edward Tobinick ... rapid recovery of cognitive functions after perispinally administering ... known about the role inflammatory processes play in ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Middle ... throughout 2013 across all industries as cash rich buyers ... the differences across industries, all M&A transactions have a ... due diligence to verify the history and quality of ... considered. , But when due diligence involves a ...
(Date:6/19/2013)... Over the past five years, revenue ... has been growing at an annualized rate of 9.5% ... have supported the development of the industry including: substantial ... relatively higher drug prices in hospitals; and people's increased ... the development of chain drug retailing enterprises has also ...
(Date:6/18/2013)... Angeles, CA (PRWEB) June 19, 2013 ... of bariatric surgery, are holding complimentary weight loss seminars ... the detailed program can be accessed at their official ... minimizes surgery and recovery time. Their highly skilled panel ... to bariatric surgery. , A senior executive working ...
(Date:6/18/2013)... 18, 2013 Exposed Skin Care has finally ... acne suffers of all ages finally achieve the clear, beautiful ... products, this new acne clearing system combines the power of ... new acne from forming. , After a quick ... products are some of the most effective available on the ...
Breaking Medicine News(10 mins):Health News:Perispinally Administered Enbrel Facilitates Rapid Recovery of Cognitive Function in Patients with Alzheimer's 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3
... VANCOUVER, APRIL 1, 2009 New research funded by ... and learning difficulties for some childhood cancer survivors, especially ... in the journal Cancer , raises critical questions ... , "These are very significant findings," says Barbara Kaminsky, ...
... nurses, doctors and other front line cancer-care providers significantly ... with other healthcare workers, and with their own family, ... and Regenstrief Institute researchers published in the March issue ... , "The healthcare field is becoming more aware of ...
... new study, a therapeutic agent called sorafenib dramatically improved the ... approved in several countries for treatment of kidney and liver ... patients suffering from advanced portal hypertension, the authors suggest. Their ... a journal published by John Wiley & Sons on behalf ...
... out to adopt a child, the world pays attention. ... Malawi -- a small impoverished African nation. In ... to over a million, help is needed in many forms. ... with a mother and siblings, and the essentials of childhood ...
... physician groups clearly understand how to effectively analyze ... to be more innovative and establish more effective ... consultants The Practice Pros and Mediplay, Inc. have ... with assessing their marketing effectiveness. To take ...
... marketer of PurinaCare (R) Pet Health Insurance ( ... ( www.kgbtexas.com ) as its PR agency of ... June 2008, and is currently authorized to market pet health ... will help create and implement a strategic public relations and ...
Cached Medicine News:Health News:New research shows lower educational outcomes for survivors of childhood cancer 2Health News:Compassion fatigue: Impact on healthcare providers of caring for the terminally ill 2Health News:Compassion fatigue: Impact on healthcare providers of caring for the terminally ill 3Health News:Medication may improve portal hypertension 2Health News:In Malawi, Adoption is Not Enough 2Health News:Hey Doc, What's Your Marketing Strategy? 2Health News:Hey Doc, What's Your Marketing Strategy? 3Health News:KGBTexas Named Public Relations Agency of Record for PurinaCare(R) Pet Health Insurance 2Health News:KGBTexas Named Public Relations Agency of Record for PurinaCare(R) Pet Health Insurance 3
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... 4F, 5F, and 6F ... is ideal for coronary ... state-of-the-art technology and proprietary ... better responsiveness, optimal torque, ...
Medicine Products: